Key result
Nitrodilators are proposed to activate soluble guanylyl cyclase via a preformed nitrodilator-activated NO store within vascular smooth muscle cells, challenging traditional NO-donor models.
Why the study?
It remains unclear how nitrodilators activate cytosolic soluble guanylyl cyclase to cause vasodilation despite low membrane permeability and failure to release requisite amounts of free nitric oxide.
How do nitrodilators activate cytosolic sGC when their NO moiety is outside the cell?
How do nitrodilators activate cytosolic sGC when their NO moiety is outside the cell?
This review proposes a novel 'NANOS' paradigm for vascular NO signaling, suggesting nitrodilators activate a preformed NO store rather than directly donating NO.
No takes yet. Share an insight, caveat, or question.
Should not alter nitrodilator prescribing; leaves open experimental validation of preformed NO stores.
Liu et al. (2022) reported a review. Nitrodilators was evaluated. Nitrodilators are proposed to activate soluble guanylyl cyclase via a preformed nitrodilator-activated NO store within vascular smooth muscle cells, challenging traditional NO-donor models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: